Gentium's 1st-qtr 2008 net loss widens 27%
Italian drug developer Gentium SpA says that, in the first quarter of 2008, total revenues reached 2.7 million euros ($4.1 million), compared with 1.2 million euros in the like, year-ago period. Despite this, net loss amounted to 6.1 million euros versus 4.8 million euros, with basic and diluted net loss per share of 0.41 euros vs 0.36 euros.
The operating deficit deepened to 4.8 million euros from 4.2 million euros, and pretax loss widened to 6.1 million euros vs 4.8 million euros, as operating costs rose to L7.5 million from L5.4 million, while R&D expenses reached 3.6 million euros from 2.7 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze